TRexBio Announces Collaboration and License Agreement with Lilly to Develop and Commercialize Novel Therapies for Immune-Mediated Diseases

Collaboration leverages TRexBio’s Deep Biology platform, which maps regulatory T cell (Treg) behavior in human tissue to identify and target immune-regulatory pathways for novel therapeutic development